Johnson & Johnson (JNJ) reported strong financial performance in Q2 2024, with revenues of $22.4 billion, reflecting a year-over-year increase of 6.6%. Despite net income declining to $4.7 billion from $5.1 billion year-over-year, adjusted net earnings improved by 10.2%, demonstrating operational resilience amidst challenging market conditions. The strong performance was characterized by significant growth in both the Innovative Medicine and MedTech segments, with Innovative Medicine achieving $14.5 billion in sales, up 7.8%. CEO Joaquin Duato emphasized the company's robust pipeline and strategic acquisitions as drivers for sustained growth. Challenges include pressures from COVID-19 vaccine sales, competitive market dynamics, and regulatory changes. The outlook remains positive as JNJ navigates these hurdles, focusing on innovation and market leadership.